Evidence map›Paper›PMID 39133873›Full record

ArticleeLife2024

Prdm1 positively regulates liver Group 1 ILCs cancer immune surveillance and preserves functional heterogeneity.

Jitian He, Le Gao, Peiying Wang, Wing Keung Chan, Yiran Zheng, Yumo Zhang, Jiaman Sun, Xue Li, Jiming Wang, Xiao-Hong Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. MCell death & disease · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jitian He *Institute of Medical Engineering & Translational Medicine, Tianjin University, Tianjin, China.ORCID https://orcid.org/0009-0008-8425-3481
Le Gao *Institute of Medical Engineering & Translational Medicine, Tianjin University, Tianjin, China.
Peiying Wang *Institute of Medical Engineering & Translational Medicine, Tianjin University, Tianjin, China.
Wing Keung ChanDepartment of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, United States.ORCID https://orcid.org/0000-0002-5257-1521
Yiran ZhengInstitute of Medical Engineering & Translational Medicine, Tianjin University, Tianjin, China.
Yumo ZhangInstitute of Medical Engineering & Translational Medicine, Tianjin University, Tianjin, China.
Jiaman SunInstitute of Medical Engineering & Translational Medicine, Tianjin University, Tianjin, China.
Xue LiDepartment of Basic Medicine, Haihe Hospital, Tianjin University, Tianjin, China.
Jiming WangTianjin Economic-Technological Development Area (TEDA) Hospital, Tianjin, China.
Xiao-Hong Li *Institute of Medical Engineering & Translational Medicine, Tianjin University, Tianjin, China.
Huaiyong Chen *Department of Basic Medicine, Haihe Hospital, Tianjin University, Tianjin, China.
Zhouxin Yang *Zhejiang Provincial Key Lab of Geriatrics and Geriatrics Institute of Zhejiang Province, Zhejiang Hospital, Hangzhou, China.
Youwei Wang *Institute of Medical Engineering & Translational Medicine, Tianjin University, Tianjin, China.ORCID https://orcid.org/0000-0002-1736-1203

Funding

National Key Research and Development Plan of China 2022YFF1202901National Natural Science Foundation of China 82372801Natural Science Foundation of Tianjin 21JCZDJC00430Natural Science Foundation of Tianjin 23JCYBJC01370Natural Science Foundation of Tianjin 23JCYBJC01560Science and Technology Planning Project of Tianjin Municipal Education Commission 2022YGYB14The Zhejiang Provincial Natural Science Foundation of China LY21H150002
6 · The paper itself

Abstract

Group 1 innate lymphoid cells (ILCs) comprise conventional natural killer (cNK) cells and type 1 innate lymphoid cells (ILC1s). The main functions of liver cNK cells and ILC1s not only include directly killing target cells but also regulating local immune microenvironment of the liver through the secretion of cytokines. Uncovering the intricate mechanisms by which transcriptional factors regulate and influence the functions of liver cNK cells and ILC1s, particularly within the context of liver tumors, presents a significant opportunity to amplify the effectiveness of immunotherapies against liver malignancies. Using Ncr1-drived conditional knockout mouse model, our study reveals the regulatory role of

Indexed as

Liver NeoplasmsMice, KnockoutPositive Regulatory Domain I-Binding Factor 1AnimalsAntigens, LyGranzymesImmunity, InnateImmunologic SurveillanceInterferon-gammaKiller Cells, NaturalLiverLymphocytesMiceMice, Inbred C57BLNatural Cytotoxicity Triggering Receptor 1PerforinAntigens, LyGranzymesGzmb protein, mouseInterferon-gammaNatural Cytotoxicity Triggering Receptor 1Ncr1 protein, mousePerforinPositive Regulatory Domain I-Binding Factor 1Prdm1 protein, mouseimmune surveillanceimmunologyinflammationinnate lymphoid cellslivermouse

Identifiers

PMID39133873
PMCPMC11318973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.